We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prophylactic Anticoagulation With Intermediate-Dose Certoparin in Vascular-Risk Pregnancies—The PACER-VARP Registry.
- Authors
Grünewald, Martin; Häge, Esther; Lehnert, Stephanie; Maier, Christiane; Schimke, Alexandra; Bramlage, Peter; Güth, Martina
- Abstract
The management of pregnant women at increased risk of thromboembolic/other vascular events is still a matter of debate. In a single-center, retrospective, observational trial, we analyzed the safety and efficacy of prophylactic anticoagulation with certoparin in pregnant women at intermediate- or high-risk by EThIG criteria of thromboembolic/other vascular events. Subcutaneous certoparin 8,000 IU once daily was administered immediately after pregnancy confirmation and continued for 6 weeks postpartum. We investigated 74 pregnancies (49 women; mean age 31.8 years; weight 77.3 kg). Most prevalent risk factors were factor V Leiden mutation (40.5%), thrombogenic factor II mutation (12.2%) and protein S deficiency (8.1%). In 76 control pregnancies prior to registry inclusion/without anticoagulation there were 14 cases [18.4%] of venous thromboembolism (between week 7 gestation and week 8 postpartum); 63.2% pregnancies resulted in abortion (median week 8.6 gestation). With certoparin anticoagulation, thromboembolism was 1.4%, exclusively non-major bleeding was 4.1% and abortion was 10.8%. One case of pre-eclampsia necessitating obstetric intervention occurred. Prophylactic anticoagulation with intermediate-dose certoparin throughout pregnancies at increased venous vascular risk was safe and effective.
- Subjects
LEIDEN (Netherlands); ACTIVATED protein C resistance; FACTOR V Leiden; PROTEIN S deficiency; PREGNANT women; ANTICOAGULANTS; PREGNANCY
- Publication
Clinical & Applied Thrombosis/Hemostasis, 2021, Vol 27, p1
- ISSN
1076-0296
- Publication type
Article
- DOI
10.1177/10760296211016550